Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC).

(2017) R. Pili et al.   JOURNAL OF CLINICAL ONCOLOGY

Blockade of Tumor Necrosis Factor   Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy

(2010) Y. Meng et al.   CANCER RESEARCH

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

(2010) John T Isaacs   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

(2010) Anders Olsson et al.   Molecular Cancer

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

(2009) O Bratt et al.   BRITISH JOURNAL OF CANCER

Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: A pilot study in men with prostate cancer

(2009) Supriya Chopra et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

(2008) Eric M. Horwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Repeated tumor pO2 measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy

(2008) Huagang Hou et al.   RADIOTHERAPY AND ONCOLOGY